Thrivent Financial for Lutherans reduced its stake in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 33.0% in the fourth quarter, according to the company in its most recent 13F filing with ...

Shares of Denali Therapeutics Inc. (NASDAQ:DNLI – Get Free Report) have been given a consensus recommendation of “Moderate ...

Despite past failures, Denali's extensive pipeline and solid financial runway make it a compelling buy at current low stock ...

In trading on Wednesday, shares of Denali Therapeutics Inc (Symbol: DNLI) entered into oversold territory, hitting an RSI reading of 29.9, after changing hands as low as $13.86 per share.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Denali Therapeutics (DNLI – Research Report), ...

In this article, we are going to take a look at where Denali Therapeutics Inc. (NASDAQ:DNLI) stands against the other companies Bezos is investing in. Since leaving his position as CEO of Amazon ...

Denali Therapeutics’ amyotrophic lateral sclerosis (ALS) drug has racked up another clinical miss this year, leaving the company to mull the asset’s future. The therapy, dubbed DNL343 ...

A stock is considered to be oversold if the RSI reading falls below 30. In trading on Monday, shares of Denali Therapeutics Inc (Symbol: DNLI) entered into oversold territory, hitting an RSI ...

Oppenheimer analyst Jay Olson lowered the firm’s price target on Denali Therapeutics (DNLI) to $42 from $50 and keeps an Outperform rating on the shares following quarterly results and after ...